Lizhu Group: Approval for Clinical Trials of Injection Brivaracetam Microspheres

Li Zhu Group announced that its wholly-owned subsidiary, Zhuhai Li Zhu Microspheres Technology Co., Ltd., has received the "Notification of Approval for Clinical Trial of Drugs" issued by the National Medical Products Administration, approving the company's application for clinical trials of injectable brexpiprazole microspheres for the treatment of adult schizophrenia. The drug is a sustained-release microsphere formulation developed independently by the company, and as of the disclosure date of the announcement, a total of approximately 7.5264 million yuan has been directly invested in research and development. There are uncertainties in clinical trials and market access, and the company will timely disclose any progress.